• 1
    The Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 221522.
  • 2
    Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23). BMJ 1998; 316: 8238.
  • 3
    Miettinen H, Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996; 27: 20339.
  • 4
    Karalliedde J, Viberti G. Hypertension and microalbuminuria: risk factors for cardiovascular disease in diabetes. Curr Hypertens Rep 2005; 7: 12.
  • 5
    Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 38393.
  • 6
    Laakso M, Rönnemaa T, Pyörälä K, Kallio V, Puukka P, Penttilä I. Atherosclerotic vascular disease and its risk factors in non-insulin-dependent diabetic and nondiabetic subjects in finland. Diabetes Care 1988; 11: 44963.
  • 7
    Rose G, Blackburn H, Gillum RF, Prineas RJ. Cardiovascular Survey Methods, 2nd edn. Geneva: World Health Organization, 1982.
  • 8
    World Health Organization. Proposal for the Multinational Monitoring of Trends and Determinants in Cardiovascular Disease and Protocol (MONICA project). Geneva: World Health Organization, 1983; (WHO/MNC/82.1, Rev. 1).
  • 9
    Walker AE, Robins M, Weinfeld FD. The national survey of stroke. Clinical findings. Stroke 1981; 12: I1344.
  • 10
    Puukka P, Rönnemaa T, Laakso M. Quality control of blood pressure measurements in a collaborative epidemiological study. In the Nordic Region of the Biometric Society, Conf on Statistical Methods in Medicine and Pharmocology, Koge, Denmark 1986 (Abstract)
  • 11
    Van Kley H, Hale SM. Assay for protein by dye binding. Anal Biochem 1977; 81: 4857.
  • 12
    Cockcroft DW, Gault HM. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 13
    Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight are known. Ann intern Med 1916; 17: 86371.
  • 14
    Mancia G, Laurent S, Agabiti-Rosei E, et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension task force document. J Hypertens 2009; 27: 212158.
  • 15
    Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375414.
  • 16
    Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 2006; 49: 17619.
  • 17
    Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The steno hypothesis. Diabetologia 1989; 32: 21926.
  • 18
    Satchell SC, Tooke JE. What is the mechanism of microalbuminuria in diabetes: a role for the glomerular endothelium? Diabetologia 2008; 51: 71425.
  • 19
    Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001; 24: 16149.
  • 20
    Lee M, Gardin JM, Lynch JC, et al. Diabetes mellitus and echocardiographic left ventricular function in free-living elderly men and women: the cardiovascular health study. Am Heart J 1997; 133: 3643.
  • 21
    Shamseddin MK, Parfrey PS, Medscape . Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol 2011; 7: 14554.
  • 22
    Asghar O, Al-Sunni A, Khavandi K. Diabetic cardiomyopathy. Clin Sci (Lond) 2009; 116: 74160.
  • 23
    Berl T, Hunsicker LG, Lewis JB, et al. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 2005; 16: 21709.
  • 24
    Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the ongoing Telmisartan alone and in combination with Ramipril global endpoint trial study. J Hypertens 2009; 27: 13609.
  • 25
    Cooper-DeHoff RM, Gong Y, Handberg EM, et al. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 618.
  • 26
    ACCORD Study Group, Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 157585.
  • 27
    Kalaitzidis R, Bakris GL. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens 2009; 11: 3457.
  • 28
    Flynn C, Bakris GL. Blood pressure targets for patients with diabetes or kidney disease. Curr Hypertens Rep 2011; 13: 4525.
  • 29
    Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 2011; 123: 2799810.